Refer to the table below. This is a hypothetically group presentation assignment. We've chosen the drug highlighted in green on the table below for the following reasons:

• We recommend MiRo 22-709A for clinical testing as it is best for oral administration and low toxicity. 51% inhibition for its target enzyme. It has high GI absorption, can permeate BBB, does not have P-gp substrate, does not have any Lipinski violations and has high ionisation percentages at 5 8 pH. The other compounds dont meet one or more of the previously mentioned criteria.

So for the selected pre-clinical drug candidate,

Please explain how many stereoisomers are possible and how does it bind to the target? (I think it means target enzyme)

Table 3: Calculated and predicted properties the original hit, MiRe 22-401T, and three significant optimised leads